Physician profile
John D Scala
NPI 1972506160
$1,311.61
in general payments reported to CMS, 2019-2025
22 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $59.20 · 2021: $164 · 2022: $126 · 2023: $226 · 2024: $383 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $237.46 | 2024-2025 | Farxiga, Airsupra |
| Pfizer INC. | $199.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $171.83 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbvie INC. | $122.72 | 2021-2023 | Viberzi, Linzess, Ubrelvy |
| Lilly USA, LLC | $109.68 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $85.21 | 2019-2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $59.95 | 2024 | Cologuard Collection Kit |
| Kaleo, INC. | $39.13 | 2021 | |
| Sanofi Pasteur INC. | $37.53 | 2019 | |
| Gilead Sciences, INC. | $27.55 | 2019 | |
| Nestle Healthcare Nutrition INC. | $26.31 | 2021 | |
| Abbott Laboratories | $26.12 | 2025 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $24.41 | 2020 | |
| Optinose US, INC. | $21.06 | 2020 | |
| Quidel Corporation | $17.43 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.16 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $17.07 | 2023 | Quviviq |
| Therapeuticsmd, INC. | $15.48 | 2019 | |
| Cranial Technologies, INC | $15.47 | 2024 | Doc Band |
| Seqirus USA INC | $13.98 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Shire North American Group INC | $13.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Scala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.